Prosecution Insights
Last updated: November 04, 2026
Application No. 18/565,075

METHODS AND DEVICES FOR DETECTING INTRAVENOUS INFUSION INFILTRATION

Final Rejection §102§112
Filed
Nov 28, 2023
Priority
May 28, 2021 — provisional 63/194,669 +1 more
Examiner
BOUCHELLE, LAURA A
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Seattle Children’S Research Hospital (Dba Seattle Children’S Research Institute)
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
3m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
990 granted / 1234 resolved
+10.2% vs TC avg
Moderate +10% lift
Without
With
+10.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
41 currently pending
Career history
1278
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
47.0%
+7.0% vs TC avg
§102
25.7%
-14.3% vs TC avg
§112
16.0%
-24.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1234 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Arguments Applicant's arguments filed 9/4/2026 have been fully considered. Regarding the allowable subject matter, Applicant’s arguments are convincing. Claims 29 and 40 are allowable over the prior art of record. Regarding the 102 and 103 rejections, the examiner agrees that the amendments to the claims overcome the prior art of record and therefore the rejections are withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 27, 32, 36 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 27, claim 22 calls for a conduit comprising an absorbent material coupled to the first side of the patch, the absorbent material being in communication with the dye. This feature can be seen in fig. 3. Claim 27 further calls for the absorbent material to be disposed around a perimeter of the first side of the patch. This is not the location of the conduit 314 containing the absorbent material in combination with the dye packet. Therefore, there is no support for the combination of elements in this claim. Regarding claim 32, the embodiment comprising the encapsulated dye as recited in claim 31 is disclosed as indicating fluid leakage, but the visible indication is not revealed in response to swelling. Regarding claim 36, the embodiment comprising the encapsulated dye is disclosed as indicating fluid leakage but not swelling. Claim Rejections - 35 USC § 102 The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claim(s) 31 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Koyama et al (US 2016/0166757). Regarding claim 31, Koyama discloses a method comprising: adhering, by a patch comprising at least one visible indicator, to skin of a patient having an intravenous (IV) insertion site (abstract; page 4, para. 0045; fig. 3); and outputting, by the at least one visible indicator, at least one visible indication of IV infiltration of the patient by causing the patch to change color by wicking, by an absorbent material in the patch, liquid leaking from the IV insertion site to an encapsulated dye in the patch (page 5, paras. 0054, 0055). Allowable Subject Matter Claims 22-25, 27, 29, 37-43 are allowed. The following is an examiner’s statement of reasons for allowance: the subject matter of the claims listed above could not be found and was not suggested by the prior art of record. Regarding claim 22, the prior art fails to teach or fairly suggest a patch having an adhesive disposed on a perimeter of the second side, a dye packet encapsulating a dye, and a conduit comprising an absorbent material coupled to the first side of the patch, the absorbent material being in communication with the dye, in combination with the features of the invention, substantially as claimed. See prior office action for additional reasons for allowance. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LAURA A BOUCHELLE whose telephone number is (571)272-2125. The examiner can normally be reached Mon-Fri 8:00-5:00 CST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bhisma Mehta can be reached at 571-272-3383. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. LAURA A. BOUCHELLE Primary Examiner Art Unit 3783 /LAURA A BOUCHELLE/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Nov 28, 2023
Application Filed
Jun 04, 2026
Non-Final Rejection mailed — §102, §112
Sep 04, 2026
Response Filed
Sep 18, 2026
Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779147
FILTER ASSEMBLY
2y 11m to grant Granted Nov 03, 2026
Patent 12773550
FLUORO-LESS SYSTEM AND METHOD FOR DELIVERING CATHETER-BASED BLOOD PUMPS
3y 12m to grant Granted Oct 27, 2026
Patent 12773490
INTRAVENOUS DELIVERY OF LARGE VOLUMES OF GAS WITH HIGHLY PRESSURIZED SUPERSATURATED SOLUTION
3y 1m to grant Granted Oct 27, 2026
Patent 12766219
BIO-ABSORBABLE DISPERSIBLE RAPIDLY DEPLOYABLE WOUND INTERFACE
3y 0m to grant Granted Oct 20, 2026
Patent 12766293
CATHETER HUB
2y 4m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
90%
With Interview (+10.3%)
3y 2m (~3m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1234 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month